Sulindac

"Sulindac" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Descriptor ID	D013467
MeSH Number(s)	D02.455.426.559.847.486.875 D04.615.486.875
Concept/Terms	Sulindac Sulindac Apo-Sulin Apo-Sulin Apo Sulin Arthrobid Arthrobid Clinoril Clinoril Arthrocine Klinoril Sulindal Sulindal Chibret Kenalin Kenalin MK-231 MK-231 MK 231 MK231 Novo-Sundac Novo-Sundac Novo Sundac Nu-Sulindac Nu-Sulindac Nu Sulindac Aclin Aclin Copal Copal

Below are MeSH descriptors whose meaning is more general than "Sulindac".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Indenes [D02.455.426.559.847.486]
Sulindac [D02.455.426.559.847.486.875]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Indenes [D04.615.486]
Sulindac [D04.615.486.875]

Below are MeSH descriptors whose meaning is related to "Sulindac".

Below are MeSH descriptors whose meaning is more specific than "Sulindac".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Sulindac" by people in this website by year, and whether "Sulindac" was a major or minor topic of these publications.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	2	0	2
2003	1	0	1
2011	1	0	1
2012	0	1	1
2013	1	0	1
2015	1	0	1
2016	0	1	1
2018	0	1	1

Below are the most recent publications written about "Sulindac" by people in Profiles.

Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 05 01; 4(5):671-677.

View in: PubMed
Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA. 2016 Mar 22-29; 315(12):1266-75.

View in: PubMed
Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015 Dec; 6:287-296.

View in: PubMed
Einbond LS, Mighty J, Kashiwazaki R, Figueroa M, Jalees F, Acuna UM, Le Gendre O, Foster DA, Kennelly EJ. Garcinia benzophenones inhibit the growth of human colon cancer cells and synergize with sulindac sulfide and turmeric. Anticancer Agents Med Chem. 2013 Dec; 13(10):1540-50.

View in: PubMed
Borgegard T, Jur?us A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater AC, Li T, Singh R, Eriksson H, Lundkvist J. First and second generation ?-secretase modulators (GSMs) modulate amyloid-? (A?) peptide production through different mechanisms. J Biol Chem. 2012 Apr 06; 287(15):11810-9.

View in: PubMed
Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012 Mar 15; 83(6):715-22.

View in: PubMed
Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther. 2003 Sep; 2(9):885-92.

View in: PubMed
Chen X, Li N, Wang S, Hong J, Fang M, Yousselfson J, Yang P, Newman RA, Lubet RA, Yang CS. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis. 2002 Dec; 23(12):2095-102.

View in: PubMed
Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002 Mar; 122(3):641-5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals